Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + terbutaline is a combination of two small molecule drugs used primarily for respiratory conditions. Budesonide is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory agent, reducing inflammation in the airways and other tissues. Terbutaline is a selective beta-2 adrenergic receptor agonist that functions as a bronchodilator by relaxing smooth muscle in the bronchial tubes, thereby improving airflow and relieving symptoms such as wheezing and shortness of breath. This combination may be considered for use in asthma or chronic obstructive pulmonary disease (COPD), leveraging both anti-inflammatory and bronchodilatory effects[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + terbutaline.